The Translational Oncology and Therapeutics Research Group experts work collaboratively in a national and international capacity to understand cancer biology, causes and prevention.
The world-renowned research specialists and sub-specialists in the Translational Oncology and Therapeutics Research Group are working to uncover new processes and design novel treatments for patients so that each individual gets a customized.
The Translational Oncology and Therapeutics Research Group is currently funded through several sources:
Zhiwei Hu, MD, PhD
- National Institutes of Health - National Cancer Institute (R21 - CA216697)
- The 2019 I-Corps@Ohio Program Award
Anna Vilgelm, MD, PhD
- National Institutes of Health - National Cancer Institute (R37 CA233770)
Other Funding
- Amblessed Onuma, MD, has been awarded NIH T32 training grant (NIH 2T32AI106704-06) entitled Advanced Research Training in Immunology for Surgical Trainees (ARTIST) from the OSU Department of Surgery.
- Amblessed Onuma, MD, also received the Association for Academic Surgery (AAS) Trainee Research Fellowship Grant in 2019.
- Yujia Xia, MD, PhD, was awarded the Early Career Investigator Award in Basic Science by the American Association for the Study of Liver Diseases (AASLD).
- Hongji Zhang, MD, PhD, received the American Association of Immunologists (AAI) Travel Grant to present his research at the 17th International Congress of Immunology in Beijing, China.
Additional Opportunities
As part of the OSUCCC – James, the Translational Oncology and Therapeutics Research Group encourages its laboratory specialists and sub-specialists to apply for Pelotonia Fellowship funding as well as to donate and fundraise for cancer research through Pelotonia.
Funded in 2008, Pelotonia has raised millions of dollars for cancer research. The Pelotonia Fellowship Program provides an opportunity to train talented and promising undergraduate, graduate, medical and postdoctoral students to assist them with becoming independent cancer researchers.